- Home
- CSTL vs CTO Comparison
CSTL vs CTO Comparison
Compare CSTL & CTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- CTO
- Stock Information
- Founded
- CSTL 2007
- CTO 1902
- Country
- CSTL United States
- CTO United States
- Employees
- CSTL N/A
- CTO N/A
- Industry
- CSTL Medical Specialities
- CTO Real Estate Investment Trusts
- Sector
- CSTL Health Care
- CTO Real Estate
- Exchange
- CSTL Nasdaq
- CTO Nasdaq
- Market Cap
- CSTL 558.7M
- CTO 589.6M
- IPO Year
- CSTL 2019
- CTO N/A
- Fundamental
- Price
- CSTL $16.75
- CTO $18.44
- Analyst Decision
- CSTL Strong Buy
- CTO Strong Buy
- Analyst Count
- CSTL 6
- CTO 3
- Target Price
- CSTL $38.33
- CTO $23.00
- AVG Volume (30 Days)
- CSTL 548.5K
- CTO 232.8K
- Earning Date
- CSTL 05-05-2025
- CTO 05-01-2025
- Dividend Yield
- CSTL N/A
- CTO 8.26%
- EPS Growth
- CSTL N/A
- CTO N/A
- EPS
- CSTL N/A
- CTO N/A
- Revenue
- CSTL $347,083,000.00
- CTO $132,203,000.00
- Revenue This Year
- CSTL N/A
- CTO $19.25
- Revenue Next Year
- CSTL $1.80
- CTO $8.47
- P/E Ratio
- CSTL N/A
- CTO N/A
- Revenue Growth
- CSTL 38.43
- CTO 17.48
- 52 Week Low
- CSTL $15.70
- CTO $16.12
- 52 Week High
- CSTL $35.84
- CTO $21.15
- Technical
- Relative Strength Index (RSI)
- CSTL 34.74
- CTO 55.49
- Support Level
- CSTL $15.84
- CTO $17.63
- Resistance Level
- CSTL $17.49
- CTO $18.35
- Average True Range (ATR)
- CSTL 0.90
- CTO 0.32
- MACD
- CSTL -0.18
- CTO 0.07
- Stochastic Oscillator
- CSTL 22.73
- CTO 94.25
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.